Gene · 580
NIH grants2,093
NIH grants whose papers are about the gene, through NIH's grant-paper links.
81 to 100 of 2,093
Download this page as JSON| Grant | Title | BARD1 papers | Newest fiscal year |
|---|---|---|---|
| R01AG011085 | Ubiquitin‐mediated proteolysis and cell cycle control | 3 | 2025 |
| R01CA228198 | Polygenic Risk Prediction of Breast Cancer for Women of African Descent | 3 | 2025 |
| R01CA236606 | Helicase regulation during homologous recombination | 3 | 2025 |
| R01CA244261 | Mechanistic characterization of the cell cycle-dependent DNA repair pathway- Resubmission | 3 | 2025 |
| R01CA268641 | Bladder cancer PD-L1 control of homologous recombination: Basic mechanisms applied to novel treatments | 3 | 2025 |
| R50CA221836 | Statistical modeling to support population and translational cancer research | 3 | 2025 |
| T32CA009582 | Biochemical and Chemical Training for Cancer Research | 3 | 2025 |
| T32CA009615 | Cancer Center Research Training Program | 3 | 2025 |
| T32CA128583 | Research Training in Childhood Cancer | 3 | 2025 |
| T32CA148724 | Cancer Biology Training Program | 3 | 2025 |
| U10CA180821 | Alliance for Clinical Trials in Oncology Operations Center - GY11 Funded Extension | 3 | 2025 |
| U10CA180888 | SWOG Network Group Operations Center of the NCTN | 3 | 2025 |
| U54CA118623 | 2/3 Morehouse School of Medicine/Tuskegee University/ University of Alabama at Birmingham O'Neal Comprehensive Cancer Center Partnership | 3 | 2025 |
| UM1CA186709 | DF/HCC Preclinical Translation-Focused Clinical Investigator to Bridge PDXNet and the ETCTN | 3 | 2025 |
| ZIABC010998 | Therapy Resistance Mechanisms for Cancer | 3 | 2025 |
| ZIACP010126 | Hormone-Related Cancers | 3 | 2025 |
| ZIACP010144 | Clinical Genetic Studies of Familial and Hereditary Cancer Syndromes | 3 | 2025 |
| ZIAES044005 | Environmental and Genetic Risk Factors For Breast Cancer: The Sister Study | 3 | 2025 |
| ZIAES102245 | The Two Sister Study | 3 | 2025 |
| F30CA278370 | The Mechanistic Role of BRCA1-BARD1 DNA and RAD51 Binding in DNA Double-Strand Break Repair | 2 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/580/grants?page=5